Computational biology, bioinformatics and systems biology: (i) development of methods and (ii) applications in microorganisms and plants, considering several scales: from molecular (metabolic pathways, signaling and genetic regulation) to that of populations and ecosystems (microbiomes; microorganism-plant interactions).

The group studies the cellular and molecular mechanisms involved in the production of different types of neurons and glia. These mechanisms generate cell differentiation trajectories that result in different neuronal and glial types. We aim to mimic these cell specification trajectories in order to produce neuronal and glial types of therapeutic interest. These cell types would make it possible to replace cells that are lost in certain neurological disorders.

Our research focuses on understanding the immune response's intricacies during infection, particularly the activation of B lymphocytes that produce antibodies and memory cells. We study the metabolic changes in these cells, known as Germinal Centers (GC), during their initiation, progression, and termination. We have discovered the role of mitochondria in GC reactions and how B cell metabolism influences both B and T cells' functions, which we term "metabolic communication." We use advanced techniques to analyze B cell metabolism and aim to identify molecular mediators of this process.

The research focuses on understanding how genetic information is read and translated into different cell types during development. This involves studying processes like transcription and mitosis, which are essential for cell diversity and growth. Transcription, the first step of reading DNA, is crucial for establishing gene expression patterns in different cell lineages. While mitosis ensures the correct number of cells, it also silences transcription temporarily.

Our research focuses on developing new phage-assisted accelerated evolution techniques for engineering proteins, targeting the re-engineering of gene regulation, and phages for innovative antimicrobial development. Additionally, we explore the creation of neuromorphic gene circuits in bacteria, aiming to develop new forms of living artificial intelligence. More information is available at: http://jaramillolab.org

Our focus is on T-cell lymphoblastic leukaemia/lymphoma (T-LBL and T-ALL), where we aim to identify new molecular biomarkers and develop more effective treatments. We integrate genomics, transcriptomics, and proteomics to uncover driver-molecular mechanisms. We found γ-secretase inhibitors' effectiveness depends on MYC gene dosage and revealed non-apoptotic functions of FADD protein in these neoplasms. Combined radiation regimens showed promise in tumor control.

Our research focuses on cell replacement therapy as a treatment for neurological diseases like Parkinson's. We aim to understand how stem cells and replacement therapies can restore cellular functions and treat diseases. We explore the basic biology of stem cells and their potential to mature into functional neurons. Additionally, we're developing technologies for externally controllable bioimplants of therapeutic cells. Our goal is to enhance the treatment of neurodegenerative diseases through basic research and cell therapy.

Our group is interested in finding out how post-translational modifications of proteins contribute both to cell-autonomous transformation and permissive tumour micro-environments in response to hormonal stress or obesity, and its influence on aberrant proliferation, DNA damage response or aberrant migration and angiogenesis processes, using cellular models and mice models of mammary glands development.

Our research focuses on understanding the mechanisms by which T cells recognize antigens presented by Major Histocompatibility Complex (MHC) molecules and how this recognition activates immune responses. We investigate the organization of T cell receptors (TCRs) into nanoclusters, which allows T cells to become activated even with few peptide-bound MHC molecules. Our goal is to apply this knowledge to develop improved versions of recombinant immune receptors for cancer immunotherapy.